Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$0.44 ▼ -0.02
(-3.44%)
MKT CAP: $3.6M • VOL: 113.5K
52W L $0 52W H $8
ROARABLE / RQD
D- • 42/100
PIOTROSKI
3 / 9
QCLS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.8M | -$10.2M | -$17.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$11.6M | -$23.4M | -$4.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.1M | -$9.0M | -$13.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$9.1M | -$9.0M | -$13.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -37.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $987.0K | $173.2K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $21.8M | $9.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QCLS.